UCLA researcher demonstrates new ways to assess drug treatment in HIV-infected patients.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D011379:Prognosis; D012367:RNA, Viral / Q000032:analysis; D011897:Random Allocation; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000032:analysis
D019380:Anti-HIV Agents; D015415:Biomarkers; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D001613:beta 2-Microglobulin; D015215:Zidovudine